// startup autopsy
VIRxSYS
Gene therapy for HIV that ran out of time and capital
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: VIRxSYS underestimated the capital intensity and timeline required to bring a lentiviral gene therapy through FDA approval for HIV.
Key Events Timeline
FOUNDING
VIRxSYS is founded in Maryland, USA, to pursue lentiviral gene therapy approaches for HIV and other diseases.
FUNDING
VIRxSYS secures early-stage funding and initiates preclinical development of its HIV gene therapy vector platform.
FUNDING
Final funding round closes, bringing total raised to $84.8M. Company enters Phase I/II clinical trials for its HIV therapy.
PIVOT
Clinical results prove insufficient for advancement. VIRxSYS attempts to restructure and seek partnership deals without success.
SHUTDOWN
VIRxSYS shuts down operations after exhausting its $84.8M in funding without achieving a commercially viable therapy.